Literature DB >> 20404127

Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.

Margot E Grinwis1, Christopher D Sibley, Michael D Parkins, Christina S Eshaghurshan, Harvey R Rabin, Michael G Surette.   

Abstract

Organisms belonging to the Streptococcus milleri group (SMG) are known for their role in pyogenic infections but have recently been implicated as etiological agents of pulmonary exacerbation in adult patients with cystic fibrosis (CF). The prolonged exposure of CF patients to antibiotics prompted us to investigate the susceptibility profiles of 118 SMG isolates from the airways of CF patients to 12 antibiotics compared to 43 SMG isolates from patients with invasive infections. We found that approximately 60% of all isolates failed to grow using the standard medium for disc diffusion, Mueller-Hinton blood agar (MHBA), so we explored the usefulness of brain heart infusion (BHI) agar for susceptibility testing. Zone-of-inhibition comparisons between BHI and MHBA showed strong correlations for six antibiotics, and interpretations were similar for both medium types. For ceftriaxone and cefepime, both groups of isolates were highly susceptible. Tetracycline resistance levels were comparable between the two groups (22% in CF isolates and 17.4% in invasive isolates). However, more than half of the CF isolates were not susceptible to azithromycin, erythromycin, and clindamycin, compared to 11%, 13%, and 6.5% of invasive isolates, respectively. There were 5-fold and 8-fold increased risks of azithromycin and clindamycin resistance, respectively, for the isolates from the airways of CF patients relative to the invasive isolates. Macrolide resistance was strongly linked to chronic azithromycin therapy in CF patients. This study shows that BHI agar is a suitable alternative for antimicrobial susceptibility testing for the SMG and that SMG isolates from the airways of CF patients are more resistant to macrolides and clindamycin than strains isolated from patients with invasive infections.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20404127      PMCID: PMC2897290          DOI: 10.1128/AAC.01845-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  48 in total

Review 1.  Clinically significant infections with organisms of the Streptococcus milleri group.

Authors:  John Belko; Donald A Goldmann; Ann Macone; Anita K Zaidi
Journal:  Pediatr Infect Dis J       Date:  2002-08       Impact factor: 2.129

2.  Bacteriology of abscesses of the central nervous system: a multicentre prospective study.

Authors:  J de Louvois; P Gortavai; R Hurley
Journal:  Br Med J       Date:  1977-10-15

Review 3.  Streptococcus anginosus ("Streptococcus milleri"): the unrecognized pathogen.

Authors:  K L Ruoff
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

4.  Antimicrobial susceptibilities of species of viridans streptococci.

Authors:  A M Bourgault; W R Wilson; J A Washington
Journal:  J Infect Dis       Date:  1979-09       Impact factor: 5.226

5.  Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial.

Authors:  A Equi; I M Balfour-Lynn; A Bush; M Rosenthal
Journal:  Lancet       Date:  2002-09-28       Impact factor: 79.321

6.  Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

Authors:  J Wolter; S Seeney; S Bell; S Bowler; P Masel; J McCormack
Journal:  Thorax       Date:  2002-03       Impact factor: 9.139

7.  Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial.

Authors:  Harris R Stutman; Jay M Lieberman; Eliezer Nussbaum; Melvin I Marks
Journal:  J Pediatr       Date:  2002-03       Impact factor: 4.406

8.  Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

Authors:  Lisa Saiman; Bruce C Marshall; Nicole Mayer-Hamblett; Jane L Burns; Alexandra L Quittner; Debra A Cibene; Sarah Coquillette; Ann Yunker Fieberg; Frank J Accurso; Preston W Campbell
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

9.  Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection.

Authors:  T Jensen; S S Pedersen; S Garne; C Heilmann; N Høiby; C Koch
Journal:  J Antimicrob Chemother       Date:  1987-06       Impact factor: 5.790

10.  Microbiology of pyogenic liver abscess.

Authors:  J C Moore-Gillon; S J Eykyn; I Phillips
Journal:  Br Med J (Clin Res Ed)       Date:  1981-09-26
View more
  8 in total

Review 1.  Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Authors:  M C Gaspar; W Couet; J-C Olivier; A A C C Pais; J J S Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-26       Impact factor: 3.267

2.  Antibiotic resistance in Prevotella species isolated from patients with cystic fibrosis.

Authors:  Laura J Sherrard; Kathryn A Graham; Stef J McGrath; Leanne McIlreavey; Joseph Hatch; Marianne S Muhlebach; Matthew C Wolfgang; Deirdre F Gilpin; J Stuart Elborn; Thamarai Schneiders; Michael M Tunney
Journal:  J Antimicrob Chemother       Date:  2013-05-21       Impact factor: 5.790

3.  Prevalence and impact of Streptococcus pneumoniae in adult cystic fibrosis patients: a retrospective chart review and capsular serotyping study.

Authors:  Christina S Thornton; Erin L Brown; Joenel Alcantara; Harvey R Rabin; Michael D Parkins
Journal:  BMC Pulm Med       Date:  2015-05-02       Impact factor: 3.317

4.  Draft Genome Sequence of Streptococcus anginosus BVI, a New Vaginal Pathogen Candidate.

Authors:  Andres Zuñiga-Bahamon; Fabian Tobar-Tosse; Jose Guillermo-Ortega; Daniel Wibberg; Andreas Tauch
Journal:  Genome Announc       Date:  2016-12-15

5.  Draft Genome Sequence of Streptococcus anginosus UMB7768, Isolated from a Woman with Recurrent UTI Symptoms.

Authors:  Sarah Miller; Taylor Miller-Ensminger; Adelina Voukadinova; Alan J Wolfe; Catherine Putonti
Journal:  Microbiol Resour Announc       Date:  2020-05-21

6.  Host cytokine responses distinguish invasive from airway isolates of the Streptococcus milleri/anginosis group.

Authors:  Julienne C Kaiser; Chris P Verschoor; Michael G Surette; Dawn M E Bowdish
Journal:  BMC Infect Dis       Date:  2014-09-11       Impact factor: 3.090

7.  Group B streptococcus (GBS) is an important pathogen in human disease- but what about in cystic fibrosis?

Authors:  Kate Skolnik; Austin Nguyen; Christina S Thornton; Barbara Waddell; Tyler Williamson; Harvey R Rabin; Michael D Parkins
Journal:  BMC Infect Dis       Date:  2017-10-02       Impact factor: 3.090

8.  Inflammation in children with cystic fibrosis: contribution of bacterial production of long-chain fatty acids.

Authors:  Erin Felton; Aszia Burrell; Hollis Chaney; Iman Sami; Anastassios C Koumbourlis; Robert J Freishtat; Keith A Crandall; Andrea Hahn
Journal:  Pediatr Res       Date:  2021-03-02       Impact factor: 3.756

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.